- FDA lifts hold on Adolor's Entereg in chronic opioid bowel dysfunction; GSK may opt out of agreement for drug in this indication
- FDA approves Abbott's Xience V everolimus-eluting stent system for coronary artery disease
- In Brief: VioQuest Pharmaceuticals Inc.
- FDA advisory committee recommends developers of diabetes drugs include cardiovascular safety, efficacy data
- FDA cautions against using protein in cervical spine
Home :: Psychiatry :: Psychiatry Conferences
AGS 2007 Annual Scientific Meeting
May 2-6, 2007 Seattle, WA- Depression associated with higher discharge-related failure rate, longer length of stay in nursing homes, study suggests
- Sleep hygiene may improve sleep for older, hospitalized patients
- Insomnia affects many older adults, needs to be treated
- Sedating antihistamines often prescribed inappropriately for older adults with insomnia
- Cleveland Clinic implements geriatrics rotation for its students
APSS SLEEP 2007
June 9-14, 2007 Minneapolis, MN- Insomnia represents potentially large financial liability for employers, research indicates
- Patients with insomnia, comorbid depression have more severe insomnia at baseline relative to patients with primary insomnia, other comorbidities
- Sublingual transmucosal zolpidem effective, well-tolerated among individuals with MOTN insomnia, findings show
- Eszopiclone demonstrates moderate to strong effect sizes on sleep outcomes relative to placebo in patients with primary insomnia, insomnia with comorbidities
- New research offers insight into pathophysiology of insomnia, potential targets for treatment
APA 2007 Annual Meeting - Insomnia track
May 19-24, 2007 San Diego, CA- Researchers outline strategies to improve recognition, diagnosis, treatment of insomnia
- Cognitive behavioral therapy, pharmacologic therapy can effectively manage patients with insomnia, expert panel agrees
- NG2-73 reduces latency to persistent sleep in model of transient insomnia, Phase II data show
- Zolpidem CR effective for long-term use on as-needed basis among individuals with primary insomnia
- Ramelteon safe, effective in treatment of insomnia among women in multiple clinical trials
APA 2007 Annual Meeting - ADHD track
May 19-24, 2007 San Diego, CA- Children, adults, patients with substance use disorders can receive appropriate diagnosis, treatment for ADHD
- OROS methylphenidate shows benefits in patients with ADHD who have comorbid mood, anxiety disorders, concomitant drug therapy in trial
- Personality characteristics among adults with ADHD dependent on substance use disorder, study shows
- Experts highlight cognitive symptoms of ADHD, efficacy of available treatments
- ADHD associated with high rates of comorbid psychiatric disorders in children, adults of both sexes, studies show
U.S. Psychiatric & Mental Health Congress 2007
October 11-14, 2007 Orlando, FL- Guanfacine XR effective, safe in treating ADHD in children, adolescents, researchers report
- Improving outcomes in adolescents, adults with ADHD
- Lisdexamfetamine improves parent-rated measures of ADHD
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events
AACAP 54th Annual Meeting
October 23-28, 2007 Boston, MA- Childhood ADHD associated with functional deficits in young adulthood, findings suggest
- Triple-bead mixed amphetamine salts improves ADHD symptoms in adolescents during 16-hour treatment period, Phase II data indicate
- Guanfacine XR does not affect daytime sleepiness, increases evening sleepiness in children, adolescents with ADHD, safety analysis shows
- Stigma associated with ADHD prevalent, may affect receptivity to treatment
- Lisdexamfetamine beneficial for adults with ADHD, new data indicate
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Transdermal methylphenidate effectively treats ADHD, improves quality of life in children who switch from ER methylphenidate, research reveals
- Doxepin effective, well tolerated in treatment of insomnia, study data show
- Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations
- Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events
- New directions for pharmacologic treatment of insomnia
- Researchers outline strategies to improve recognition, diagnosis, treatment of insomnia
- Cognitive behavioral therapy, pharmacologic therapy can effectively manage patients with insomnia, expert panel agrees
- Children, adults, patients with substance use disorders can receive appropriate diagnosis, treatment for ADHD
- OROS methylphenidate shows benefits in patients with ADHD who have comorbid mood, anxiety disorders, concomitant drug therapy in trial
All material on this Web site is protected by copyright. Copyright © 1994-2008 by VerusMed, a ConnectivHealth company. This Web site may also contain material copyrighted by third parties.